We have three licensing partners as described below:
Merrimack Pharmaceuticals, Inc.
Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. For more information, please visit Merrimack's website at http://www.merrimack.com
Nanobiotix S.A. is a Paris, France based leading nanomedicine company dedicated to the development of new cancer treatments, by combining the advantages of nanotechnology and biotechnology. For more information, please visit the Company's website at http://www.nanobiotix.com.
Guangzhou BeBetter Medicine Technology Co., Ltd.
Guangzhou BeBetter Medicine Technology Co., Ltd. is a new drug discovery and development company founded in 2012 and based in the Guangzhou Science Park, , China. BeBetter focuses on new drugs to treat cancers and other serious diseases. BeBetter has three drug candidates which have entered the preclinical development stage.
While BeBetter is responsible for discovering optimized compounds for IND-enabling studies, PharmaEngine will be responsible for development and commercialization. For further information, please visit the Company website at http://bebettermed.cn/.